HIGHLIGHTS
- who: Magdalena Knetki-Wru00f3blewska et al. from the Department of Lung Cancer and Chest Tumours, The Maria Sku0142odowska-Curie National Research Institute of Oncology, Warsaw, Poland have published the paper: Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice, in the Journal: (JOURNAL)
- what: The authors aim to confirm the benefits and indicate predictive factors for immunotherapy in daily Methods: This study was a retrospective analysis. The aim was to identify the clinical and morphological factors that can define the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.